Notice: Prescription Drug List (PDL): Multiple Additions (2021-10-21)

Notice: Prescription Drug List (PDL): Multiple Additions (2021-10-21) The purpose of this Notice of Amendment is to notify of the addition of the following medicinal ingredients on the Prescription Drug List (PDL) for human and veterinary use: Infigratinib or its salts, Lurbinectedin or its salts or derivatives, Pemigatinib or its salts, Propylthiouracil or its salts, Sacituzumab govitecan, and Sotorasib. 2023-09-30 Health Canada open-ouvert@tbs-sct.gc.ca Health and Safetynotice of amendmentPrescription Drug ListPDLmedicinal ingredientshuman-and-veterinary useInfigratinibLurbinectedinPemigatinibPropylthiouracilSacituzumab govitecanSotorasib Notice: Prescription Drug List (PDL): Multiple Additions (2021-10-21)HTML https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2021-10-21.html Notice: Prescription Drug List (PDL): Multiple Additions (2021-10-21)HTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/liste-drogues-ordonnance/avis-concernant-modifications/additions-multiples-2021-10-21.html

The purpose of this Notice of Amendment is to notify of the addition of the following medicinal ingredients on the Prescription Drug List (PDL) for human and veterinary use: Infigratinib or its salts, Lurbinectedin or its salts or derivatives, Pemigatinib or its salts, Propylthiouracil or its salts, Sacituzumab govitecan, and Sotorasib.

Data and Resources

Similar records